ThinkCyte Launches VisionCyte to Transform Drug Discovery and Research

In a significant move that marks a new era in biotechnology, ThinkCyte has announced the pre-commercial launch of its latest innovation, the VisionCyte cell analysis platform. This announcement comes at an exciting time for researchers and scientists worldwide, coinciding with the annual Society for Laboratory Automation and Screening (SLAS) conference taking place in San Diego, California from January 27-30, 2025.

The VisionCyte platform is set to enhance the landscape of drug discovery by utilizing advanced artificial intelligence (AI) technologies alongside high-resolution morphological profiling and high-throughput capabilities. This powerful combination will enable researchers to uncover novel biomarkers, effectively accelerating the identification of new targets and hits in drug discovery processes.

As a finalist for the prestigious SLAS 2025 New Product Award, VisionCyte is positioned as a groundbreaking tool that extends ThinkCyte’s established legacy in life sciences, building upon their flagship product, VisionSort. Launched in 2023, VisionSort has already made its mark among leading biopharmaceutical companies and academic institutions across the globe.

What makes VisionCyte particularly compelling is its ability to provide significant insights into various challenging areas of research, including hematological conditions and stem cell studies. To further complement VisionCyte, ThinkCyte has introduced the Celluminate cell tracking kits, designed to enhance discovery applications where existing cell surface markers are limited. This advancement aims to address critical gaps in research on age-related diseases and other medically relevant conditions.

Waichiro Katsuda, the CEO of ThinkCyte, expressed pride in the company’s commitment to advancing life science research. He stated, "The expansion of our product portfolio reflects our unwavering commitment to advancing life science research. By introducing innovative solutions that address the evolving needs of scientists worldwide, we’re not just adding products—we’re providing the tools to accelerate discoveries in disease understanding and drug discovery to improve lives."

The complete commercial rollout of VisionCyte will occur later in 2025, with initial customer-ready units expected to become available in the second half of the year. More information about this cutting-edge platform will be on display at the ThinkCyte booth (#2632) during the SLAS conference. Additionally, interested parties can explore detailed insights on the VisionCyte platform and its capabilities on ThinkCyte's official website at thinkcyte.com/visioncyte.

Founded in 2016, ThinkCyte operates with offices in Tokyo, Japan, and Redwood City, California. The company is dedicated to the development of innovative scientific instruments that leverage integrated, multidisciplinary technologies for life science research, diagnostics, and therapeutic development. They pioneered Ghost Cytometry™, a proprietary AI-based labeling-free cell analysis and sorting technology that has garnered attention and partnerships with major global biopharmaceutical firms and academic research institutions.

As the world continues to face complex healthcare challenges, innovations like VisionCyte will play an integral role in shaping the future of drug discovery, highlighting the importance of advanced biotechnology in tackling diseases that affect millions globally. With ThinkCyte leading the charge, the horizon of life science research looks brighter than ever.